Illumina and PacBio abandon deal
DNA sequencing companies Illumina and Pacific Biosciences have abandoned their proposed $1.2 billion merger, amid increasing antitrust scrutiny in the US and the UK.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.